- Home
- BGLC vs PHIO Comparison
BGLC vs PHIO Comparison
Compare BGLC & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- PHIO
- Stock Information
- Founded
- BGLC 2017
- PHIO 2011
- Country
- BGLC Malaysia
- PHIO United States
- Employees
- BGLC N/A
- PHIO N/A
- Industry
- BGLC Medical Specialities
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- PHIO Health Care
- Exchange
- BGLC Nasdaq
- PHIO Nasdaq
- Market Cap
- BGLC 10.4M
- PHIO 12.1M
- IPO Year
- BGLC N/A
- PHIO N/A
- Fundamental
- Price
- BGLC $5.40
- PHIO $1.86
- Analyst Decision
- BGLC
- PHIO Strong Buy
- Analyst Count
- BGLC 0
- PHIO 3
- Target Price
- BGLC N/A
- PHIO $10.67
- AVG Volume (30 Days)
- BGLC 99.3K
- PHIO 8.1M
- Earning Date
- BGLC 11-14-2025
- PHIO 11-11-2025
- Dividend Yield
- BGLC N/A
- PHIO N/A
- EPS Growth
- BGLC N/A
- PHIO N/A
- EPS
- BGLC N/A
- PHIO N/A
- Revenue
- BGLC $9,551,559.00
- PHIO N/A
- Revenue This Year
- BGLC N/A
- PHIO N/A
- Revenue Next Year
- BGLC N/A
- PHIO N/A
- P/E Ratio
- BGLC N/A
- PHIO N/A
- Revenue Growth
- BGLC 4.01
- PHIO N/A
- 52 Week Low
- BGLC $2.01
- PHIO $0.97
- 52 Week High
- BGLC $15.60
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- BGLC 52.88
- PHIO 29.87
- Support Level
- BGLC $5.00
- PHIO $2.08
- Resistance Level
- BGLC $5.37
- PHIO $2.17
- Average True Range (ATR)
- BGLC 0.34
- PHIO 0.25
- MACD
- BGLC 0.02
- PHIO -0.03
- Stochastic Oscillator
- BGLC 61.14
- PHIO 5.66
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.